dapagliflozin + warfarin

This is a **combination of dapagliflozin and warfarin**, not marketed as a fixed-dose combination product but may be co-administered. **Dapagliflozin** is a small molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by inhibiting glucose reabsorption in the proximal renal tubules, leading to glycosuria; it is used primarily in type 2 diabetes, chronic kidney disease, and heart failure. **Warfarin** is a small molecule vitamin K antagonist anticoagulant that inhibits the synthesis of vitamin K-dependent clotting factors in the liver and is widely used for the prevention and treatment of thromboembolic disorders. Combined use involves independent mechanisms: dapagliflozin for glycemic and cardio-renal benefit, and warfarin for anticoagulation. Pharmacokinetic and pharmacodynamic studies show no clinically meaningful interaction between dapagliflozin and warfarin when co-administered[1].